Can artificial intelligency revolutionize drug discovery?

  • Jean-louis KrausEmail author
Curmudgeon Corner


Artificial intelligency can bring speed and reliability to drug discovery process. It represents an additional intelligence, which in any case can replace the strategic and logic creative insight of the medicinal chemist who remains the architect and molecule master designer. In terms of drug design, artificial intelligency, deep learning machines, and other revolutionary technologies will match with the medicinal chemist’s natural intelligency, but for sure never go beyond. This manuscript tries to assess the impact of the artificial intelligency on drug discovery today.


Artificial intelligence Chemistry Drug discovery Deep learning machine 



Institut de Biologie du Développement de Marseille (IBDM), Aix Marseille University and CNRS-UMR 7288 are greatly acknowledged for their financial support. We thank Mrs. Mair Richards for the manuscript’s English revision.

Curmudgeon Corner

Curmudgeon Corner is a short opinionated column on trends in technology, arts, science and society, commenting on issues of concern to the research community and wider society. Whilst the drive for super-human intelligence promotes potential benefits to wider society, it also raises deep concerns of existential risk, thereby highlighting the need for an ongoing conversation between technology and society. At the core of Curmudgeon concern is the question: What is it to be human in the age of the AI machine? -Editor.


  1. Armstrong RW, Beau J-M, Cheon SH, Christ WJ, Fujioka H, Ham WH, Hawkins LD, Jin H, Kang SH (2009) Total synthesis of palytoxin carboxylic acid and palytoxin amide. J Am Chem Soc 111:7530–7533. CrossRefGoogle Scholar
  2. Baenninger A (2004) Good chemistry: the life and legacy of valium inventor Leo Sternbach. McGraw-Hill, New York. ISBN 0-07-142617-5Google Scholar
  3. Chanteau SH, Tour JM (2003) Synthesis of anthropomorphic molecules: the Nanoputians. J Org Chem 68(23):8750–8766. CrossRefGoogle Scholar
  4. Donderwinkel SH, Van Hest JCM, Cameron NR (2017) Bio-inks for 3D bioprinting: recent advances and future prospects. Polym Chem 31:4451–4471. CrossRefGoogle Scholar
  5. Drug Development and Delivery (2018) Artificial intelligence—3Ds powering AI in drug discovery—domain expertise, deep learning and data, BenchBlog. Accessed 7 Aug 2018
  6. Fink T, Reymond J-L (2007) Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly if 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes and drug discovery. J Chem Inf Model 47:342–353. CrossRefGoogle Scholar
  7. Gordon RT (2016) The rise and fall of American growth: the U.S. standard of living since the Civil War. Princeton University Press, Princeton, ISBN 9780691175805Google Scholar
  8. Hover BM, Kim SH, Katz M, Charlop-Powers Z, Owen JG, Ternei MA, Maniko J, Estrela AB, Molina H, Park S, Perlin DS, Brady SF (2018) Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nat Microbiol 3(4):415–422. CrossRefGoogle Scholar
  9. Kimura H, Sakai Y, Fujii T (2018) Organ/body-on-a-chip based on microfluidic technology for drug discovery. Drug Metab Pharmacokinet 33:43–48CrossRefGoogle Scholar
  10. Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller A, Schäberle TF, Hughes DE, Epstein S, Jones M, Lazarides L, Steadman VA, Cohen DR, Felix CR, Fetterman KA, Millett WP, Nitti AG, Zullo AM, Chen C, Lewis K (2015) A new antibiotic kills pathogens without detectable resistance. Nature 517:455–459. CrossRefGoogle Scholar
  11. Olgac A, Türe A, Olgac S, Möller S (2019) Cloud based high throughput virtual screening in novel drug discovery. In: Kolodziej J, Gonzalez-Velez H (eds) Springer Open, pp 250–278. ISSN 0302.9703.
  12. Reymond J-L (2015) The chemical space project. Acc Chem Res 48:722–730. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institut de Biologie du Développement de Marseille (IBDM), CNRS-Inserm-Aix Marseille UniversitéProfessor Aix Marseille UniversityMarseille CedexFrance

Personalised recommendations